These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

479 related articles for article (PubMed ID: 26523836)

  • 1. Organ iron accumulation in chronically transfused children with sickle cell anaemia: baseline results from the TWiTCH trial.
    Wood JC; Cohen AR; Pressel SL; Aygun B; Imran H; Luchtman-Jones L; Thompson AA; Fuh B; Schultz WH; Davis BR; Ware RE;
    Br J Haematol; 2016 Jan; 172(1):122-30. PubMed ID: 26523836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: baseline results from the TWiTCH trial.
    Wood JC; Pressel S; Rogers ZR; Odame I; Kwiatkowski JL; Lee MT; Owen WC; Cohen AR; St Pierre T; Heeney MM; Schultz WH; Davis BR; Ware RE;
    Am J Hematol; 2015 Sep; 90(9):806-10. PubMed ID: 26087998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke prevention.
    Kwiatkowski JL; Cohen AR; Garro J; Alvarez O; Nagasubramanian R; Sarnaik S; Thompson A; Woods GM; Schultz W; Mortier N; Lane P; Mueller B; Yovetich N; Ware RE;
    Am J Hematol; 2012 Feb; 87(2):221-3. PubMed ID: 22120913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial.
    Ware RE; Davis BR; Schultz WH; Brown RC; Aygun B; Sarnaik S; Odame I; Fuh B; George A; Owen W; Luchtman-Jones L; Rogers ZR; Hilliard L; Gauger C; Piccone C; Lee MT; Kwiatkowski JL; Jackson S; Miller ST; Roberts C; Heeney MM; Kalfa TA; Nelson S; Imran H; Nottage K; Alvarez O; Rhodes M; Thompson AA; Rothman JA; Helton KJ; Roberts D; Coleman J; Bonner MJ; Kutlar A; Patel N; Wood J; Piller L; Wei P; Luden J; Mortier NA; Stuber SE; Luban NLC; Cohen AR; Pressel S; Adams RJ
    Lancet; 2016 Feb; 387(10019):661-670. PubMed ID: 26670617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease.
    Estcourt LJ; Kohli R; Hopewell S; Trivella M; Wang WC
    Cochrane Database Syst Rev; 2020 Jul; 7(7):CD003146. PubMed ID: 32716555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease.
    Estcourt LJ; Fortin PM; Hopewell S; Trivella M; Wang WC
    Cochrane Database Syst Rev; 2017 Jan; 1(1):CD003146. PubMed ID: 28094851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing cardiac and liver iron overload in chronically transfused patients with sickle cell disease.
    Badawy SM; Liem RI; Rigsby CK; Labotka RJ; DeFreitas RA; Thompson AA
    Br J Haematol; 2016 Nov; 175(4):705-713. PubMed ID: 27507431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial.
    Alvarez O; Yovetich NA; Scott JP; Owen W; Miller ST; Schultz W; Lockhart A; Aygun B; Flanagan J; Bonner M; Mueller BU; Ware RE;
    Am J Hematol; 2013 Nov; 88(11):932-8. PubMed ID: 23861242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absence of cardiac siderosis by MRI T2* despite transfusion burden, hepatic and serum iron overload in Lebanese patients with sickle cell disease.
    Inati A; Musallam KM; Wood JC; Sheikh-Taha M; Daou L; Taher AT
    Eur J Haematol; 2009 Dec; 83(6):565-71. PubMed ID: 19737308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term results using hydroxyurea/phlebotomy for reducing secondary stroke risk in children with sickle cell anemia and iron overload.
    Greenway A; Ware RE; Thornburg CD
    Am J Hematol; 2011 Apr; 86(4):357-61. PubMed ID: 21442640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease.
    Wang WC; Dwan K
    Cochrane Database Syst Rev; 2013 Nov; (11):CD003146. PubMed ID: 24226646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transfusional Iron Overload in a Cohort of Children with Sickle Cell Disease: Impact of Magnetic Resonance Imaging, Transfusion Method, and Chelation.
    Stanley HM; Friedman DF; Webb J; Kwiatkowski JL
    Pediatr Blood Cancer; 2016 Aug; 63(8):1414-8. PubMed ID: 27100139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deferasirox for iron chelation in multitransfused children with sickle cell disease; long-term experience in the East London clinical haemoglobinopathy network.
    Tsouana E; Kaya B; Gadong N; Hemmaway C; Newell H; Simmons A; Whitmarsh S; Telfer P
    Eur J Haematol; 2015 Apr; 94(4):336-42. PubMed ID: 25138173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic phlebotomy is safe in children with sickle cell anaemia and can be effective treatment for transfusional iron overload.
    Aygun B; Mortier NA; Kesler K; Lockhart A; Schultz WH; Cohen AR; Alvarez O; Rogers ZR; Kwiatkowski JL; Miller ST; Sylvestre P; Iyer R; Lane PA; Ware RE;
    Br J Haematol; 2015 Apr; 169(2):262-6. PubMed ID: 25612463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of serial serum ferritin measurements and liver iron concentration assessed by MRI in adult transfused patients with sickle cell disease.
    Tsitsikas DA; Nzouakou R; Ameen V; Sirigireddy B; Amos RJ
    Eur J Haematol; 2014 Feb; 92(2):164-7. PubMed ID: 24175986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of secondary stroke and resolution of transfusional iron overload in children with sickle cell anemia using hydroxyurea and phlebotomy.
    Ware RE; Zimmerman SA; Sylvestre PB; Mortier NA; Davis JS; Treem WR; Schultz WH
    J Pediatr; 2004 Sep; 145(3):346-52. PubMed ID: 15343189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hydroxycarbamide treatment reduces transcranial Doppler velocity in the absence of transfusion support in children with sickle cell anaemia, elevated transcranial Doppler velocity, and cerebral vasculopathy: the EXTEND trial.
    Rankine-Mullings A; Reid M; Soares D; Taylor-Bryan C; Wisdom-Phipps M; Aldred K; Latham T; Schultz WH; Knight-Madden J; Badaloo A; Lane A; Adams RJ; Ware RE
    Br J Haematol; 2021 Nov; 195(4):612-620. PubMed ID: 34291449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longitudinal MRI and Ferritin Monitoring of Iron Overload in Chronically Transfused and Chelated Children With Sickle Cell Anemia and Thalassemia Major.
    Aubart M; Ou P; Elie C; Canniffe C; Kutty S; Delos V; Graffigne C; de Montalembert M; Brousse V
    J Pediatr Hematol Oncol; 2016 Oct; 38(7):497-502. PubMed ID: 27548334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth differentiation factor-15 in young sickle cell disease patients: relation to hemolysis, iron overload and vascular complications.
    Tantawy AA; Adly AA; Ismail EA; Darwish YW; Ali Zedan M
    Blood Cells Mol Dis; 2014 Dec; 53(4):189-93. PubMed ID: 25065856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
    Nolte F; Höchsmann B; Giagounidis A; Lübbert M; Platzbecker U; Haase D; Lück A; Gattermann N; Taupitz M; Baier M; Leismann O; Junkes A; Schumann C; Hofmann WK; Schrezenmeier H
    Ann Hematol; 2013 Jan; 92(2):191-8. PubMed ID: 23073603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.